Fibroblast growth factor 23 and the risk of infection-related hospitalization in older adults

Journal of the American Society of Nephrology

Volumn 28, Issue 4, 2017, Pages 1239-1246

  Nowak, Kristen L ^a   Bartz, Traci M ^b   Dalrymple, Lorien ^d   De Boer, Ian H ^c   Kestenbaum, Bryan ^c   Shlipak, Michael G ^e,f   Garimella, Pranav S ^g   Ix, Joachim H ^h,i   Chonchol, Michel ^a  

^a UNIVERSITY OF COLORADO   (United States)

^b UNIVERSITY OF WASHINGTON   (United States)

^c UNIVERSITY OF WASHINGTON SCHOOL OF MEDICINE   (United States)

^d UNIVERSITY OF CALIFORNIA   (United States)

^e UNIVERSITY OF CALIFORNIA   (United States)

^f SAN FRANCISCO VETERANS AFFAIRS MEDICAL CENTER   (United States)

^g TUFTS MEDICAL CENTER   (United States)

^h UNIVERSITY OF CALIFORNIA   (United States)

ⁱ VA SAN DIEGO HEALTHCARE SYSTEM   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

24,25 DIHYDROXYVITAMIN D; 25 HYDROXYVITAMIN D; CALCIUM; FIBROBLAST GROWTH FACTOR 23; PARATHYROID HORMONE; PHOSPHORUS; FIBROBLAST GROWTH FACTOR;

AGED; ALBUMIN CREATININE RATIO; ARTICLE; CALCIUM BLOOD LEVEL; CHRONIC KIDNEY FAILURE; CONFIDENCE INTERVAL; CONTROLLED STUDY; DISEASE ASSOCIATION; ESTIMATED GLOMERULAR FILTRATION RATE; FEMALE; FOLLOW UP; HAZARD RATIO; HIGH RISK PATIENT; HOSPITAL INFECTION; HOSPITALIZATION; HUMAN; INCIDENCE; INFECTION RISK; LONGITUDINAL STUDY; MAJOR CLINICAL STUDY; MALE; PRIORITY JOURNAL; PROPORTIONAL HAZARDS MODEL; PROSPECTIVE STUDY; PROTEIN BLOOD LEVEL; SENSITIVITY ANALYSIS; URINE ALBUMIN CREATININE RATIO; BACTERIAL INFECTIONS; BLOOD; RISK FACTOR; STATISTICS AND NUMERICAL DATA;

AGED; BACTERIAL INFECTIONS; FEMALE; FIBROBLAST GROWTH FACTORS; HOSPITALIZATION; HUMANS; LONGITUDINAL STUDIES; MALE; PROSPECTIVE STUDIES; RISK FACTORS;

EID: 85019025987     PISSN: 10466673     EISSN: 15333450     Source Type: Journal    
DOI: 10.1681/asn.2016040401     Document Type: Article

References (30)

1. Stubbs J, Liu S, Quarles LD: Role of fibroblast growth factor 23 in phosphate homeostasis and pathogenesis of disordered mineral metabolism in chronic kidney disease. Semin Dial 20: 302-308, 2007
2. Saito H, Maeda A, Ohtomo S, Hirata M, Kusano K, Kato S, Ogata E, Segawa H, Miyamoto K, Fukushima N: Circulating FGF-23 is regulated by 1alpha, 25-dihydroxyvitamin D3 and phosphorus in vivo. J BiolChem 280: 2543-2549, 2005
3. Ix JH, Katz R, Kestenbaum BR, de Boer IH, Chonchol M, Mukamal KJ, Rifkin D, SiscovickDS, SarnakMJ, ShlipakMG: Fibroblast growth factor-23 and death, heart failure, and cardiovascular events in communityliving individuals: CHS (Cardiovascular Health Study). JAmColl Cardiol 60: 200-207, 2012
4. Kendrick J, Cheung AK, Kaufman JS, Greene T, Roberts WL, Smits G, Chonchol M; HOST Investigators: FGF-23 associates with death, cardiovascular events, and initiation of chronic dialysis. J Am Soc Nephrol 22: 1913-1922, 2011
5. Isakova T, Wahl P, VargasGS, GutiérrezOM, Scialla J, XieH, Appleby D, Nessel L, Bellovich K, Chen J, Hamm L, Gadegbeku C, Horwitz E, Townsend RR, Anderson CA, Lash JP, Hsu CY, Leonard MB, Wolf M: Fibroblast growth factor 23 is elevated before parathyroid hormone and phosphate in chronic kidney disease. Kidney Int 79: 1370-1378, 2011
6. Isakova T, Xie H, Yang W, Xie D, Anderson AH, Scialla J, Wahl P, GutiérrezOM, Steigerwalt S, He J, Schwartz S, Lo J, Ojo A, Sondheimer J, Hsu CY, Lash J, Leonard M, Kusek JW, Feldman HI, Wolf M; Chronic Renal InsufficiencyCohort (CRIC) StudyGroup: Fibroblast growth factor 23 and risks of mortality and end-stage renal disease in patients with chronic kidney disease. JAMA 305: 2432-2439, 2011
7. Curns AT, Holman RC, Sejvar JJ, Owings MF, Schonberger LB: Infectious disease hospitalizations among older adults in the United States from1990 through 2002. Arch InternMed 165: 2514-2520, 2005
8. Curns AT, Steiner CA, Sejvar JJ, Schonberger LB: Hospital charges attributable to a primary diagnosis of infectious diseases in older adults in the United States, 1998 to 2004. J AmGeriatr Soc 56: 969-975, 2008
9. Dalrymple LS, Katz R, Kestenbaum B, de Boer IH, Fried L, Sarnak MJ, ShlipakMG: The risk of infection-related hospitalization with decreased kidney function. Am J Kidney Dis 59: 356-363, 2012
10. Chonchol M, Greene T, Zhang Y, Hoofnagle AN, Cheung AK: Low vitamin D and High fibroblast growth factor 23 serum levels associate with infectious and cardiac deaths in the HEMO Study. J Am Soc Nephrol 27: 227-237, 2015
11. Bacchetta J, Salusky IB, Hewison M: Beyond mineral metabolism, is there an interplay between FGF23 and vitamin D in innate immunity? Pediatr Nephrol 28: 577-582, 2013
12. Rossaint J, Oehmichen J, Van Aken H, Reuter S, Pavenstädt HJ, Meersch M, Unruh M, Zarbock A: FGF23 signaling impairs neutrophil recruitment and host defense during CKD. J Clin Invest 126: 962-974, 2016
13. Naqvi SB, Collins AJ: Infectious complications in chronic kidney disease. Adv Chronic Kidney Dis 13: 199-204, 2006
14. Dalrymple LS, Go AS: Epidemiology of acute infections among patients with chronic kidney disease. Clin J Am Soc Nephrol 3: 1487-1493, 2008
15. Ginde AA, Mansbach JM, Camargo CA Jr.: Association between serum 25-hydroxyvitamin D level and upper respiratory tract infection in the Third National Health and Nutrition Examination Survey. Arch Intern Med 169: 384-390, 2009
16. van Etten E, Stoffels K, Gysemans C, Mathieu C, Overbergh L: Regulation of vitamin D homeostasis: Implications for the immune system. Nutr Rev 66[Suppl 2]: S125-S134, 2008
17. Liu PT, Stenger S, Li H, Wenzel L, Tan BH, Krutzik SR, Ochoa MT, Schauber J, Wu K, Meinken C, Kamen DL, Wagner M, Bals R, Steinmeyer A, Zügel U, Gallo RL, Eisenberg D, Hewison M, Hollis BW, Adams JS, Bloom BR, Modlin RL: Toll-like receptor triggering of a vitamin D-mediated human antimicrobial response. Science 311: 1770-1773, 2006
18. Jeng L, Yamshchikov AV, Judd SE, Blumberg HM, Martin GS, Ziegler TR, Tangpricha V: Alterations in vitamin D status and anti-microbial peptide levels in patients in the intensive care unit with sepsis. J Transl Med 7: 28, 2009
19. Jovanovich A, Ix JH, Gottdiener J, McFann K, Katz R, Kestenbaum B, de Boer IH, SarnakM, Shlipak MG, Mukamal KJ, Siscovick D, ChoncholM: Fibroblast growth factor 23, left ventricular mass, and left ventricular hypertrophy in community-dwelling older adults. Atherosclerosis 231: 114-119, 2013
20. Liu S, Quarles LD: How fibroblast growth factor 23 works. J Am Soc Nephrol 18: 1637-1647, 2007
21. de Boer IH, Sachs MC, Chonchol M, Himmelfarb J, Hoofnagle AN, Ix JH, Kremsdorf RA, Lin YS, Mehrotra R, Robinson-Cohen C, Siscovick DS, Steffes MW, Thummel KE, Tracy RP, Wang Z, Kestenbaum B: EstimatedGFR and circulating 24, 25-dihydroxyvitamin D3 concentration: A participant-level analysis of 5 cohort studies and clinical trials. Am J Kidney Dis 64: 187-197, 2014
22. Bosworth CR, Levin G, Robinson-Cohen C, Hoofnagle AN, Ruzinski J, Young B, Schwartz SM, Himmelfarb J, Kestenbaum B, de Boer IH: The serum 24, 25-dihydroxyvitamin D concentration, a marker of vitamin D catabolism, is reduced in chronic kidney disease. Kidney Int 82: 693-700, 2012
23. Berg AH, Powe CE, Evans MK, Wenger J, Ortiz G, Zonderman AB, Suntharalingam P, Lucchesi K, Powe NR, Karumanchi SA, Thadhani RI: 24, 25-Dihydroxyvitamin d3 and vitamin D status of community-dwelling black and white Americans. Clin Chem 61: 877-884, 2015
24. Fried LP, Borhani NO, Enright P, Furberg CD, Gardin JM, Kronmal RA, Kuller LH, Manolio TA, Mittelmark MB, Newman A, O'Leary DH, Psaty B, Rautaharju P, Russell TP, Weiler PG: The Cardiovascular Health Study: Design and rationale. Ann Epidemiol 1: 263-276, 1991
25. Jonsson KB, Zahradnik R, Larsson T, White KE, Sugimoto T, Imanishi Y, Yamamoto T, HampsonG, Koshiyama H, LjunggrenO, Oba K, Yang IM, Miyauchi A, Econs MJ, Lavigne J, Jüppner H: Fibroblast growth factor 23 in oncogenic osteomalacia and X-linked hypophosphatemia. NEngl J Med 348: 1656-1663, 2003
26. Shlipak MG, Sarnak MJ, Katz R, Fried LF, Seliger SL, Newman AB, Siscovick DS, Stehman-Breen C: Cystatin C and the risk of death and cardiovascular eventsamong elderly persons. NEngl JMed 352: 2049-2060, 2005
27. Stevens LA, Coresh J, Schmid CH, Feldman HI, Froissart M, Kusek J, Rossert J, Van Lente F, Bruce RD 3rd, Zhang YL, Greene T, Levey AS: Estimating GFR using serum cystatin C alone and in combination with serumcreatinine: Apooled analysis of 3, 418 individualswithCKD. AmJ Kidney Dis 51: 395-406, 2008
28. Shlipak MG, Fried LF, Cushman M, Manolio TA, Peterson D, Stehman-Breen C, Bleyer A, Newman A, Siscovick D, Psaty B: Cardiovascular mortality risk in chronic kidney disease: Comparison of traditional and novel risk factors. JAMA 293: 1737-1745, 2005
29. Mathew JS, Sachs MC, Katz R, Patton KK, Heckbert SR, Hoofnagle AN, Alonso A, Chonchol M, Deo R, Ix JH, Siscovick DS, Kestenbaum B, de Boer IH: Fibroblast growth factor-23 and incident atrial fibrillation: The Multi-Ethnic Study of Atherosclerosis (MESA) and the Cardiovascular Health Study (CHS). Circulation 130: 298-307, 2014
30. Stevens PE, Levin A; Kidney Disease: Improving Global Outcomes Chronic Kidney Disease Guideline Development Work Group Members: Evaluation and management of chronic kidney disease: Synopsis of the kidney disease: Improving global outcomes 2012 clinical practice guideline. Ann Intern Med 158: 825-830, 2013